UnitedHealth Group Incorporated UNH and Amedisys, Inc.’s AMED $3.3 billion merger is set to close in the second half of 2024, with Amedisys becoming a wholly-owned subsidiary of UnitedHealth. Both companies are divesting certain care centers to VitalCaring Group’s affiliate VCG Luna, to satisfy federal antitrust regulators. This move, announced recently by Amedisys in a filing with the U.S. Securities & Exchange Commission, is expected to streamline the merger process and maintain compliance with regulatory requirements. By selling these assets, the companies aim to avoid potential monopoly issues and ensure a smoother merger process. As stated in the filing, the finalization of the divestment agreement hinges on the successful completion of the UnitedHealth deal. Further financial details of the move are yet to be disclosed. UNH business Optum submitted a full-cash proposal to combine with Amedisys in June 2023. Optum’s expertise in value-based care and Amedisys’ care and quality innovation within the home were expected to drive better health outcomes at lower costs and improve patient care continuity. Optum has made some significant acquisitions over the years to strengthen its market position and boost its capabilities. In February 2023, it closed a massive $5.4 billion acquisition of LHC Group. The Optum business is crucial for the company’s diversification strategy. The technology-enabled health services business contributed more than 24% of UNH’s revenues in 2023. The unit is on track to achieve 5 million patients served in value-based care by 2024-end. Price Performance UnitedHealth shares have gained 6.6% in the past year compared with the industry’s 5.3% growth. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Key Picks UnitedHealth currently has a Zacks Rank #3 (Hold). Investors interested in the broader Medical space may look at some better-ranked players like Elevance Health, Inc. ELV and Aura Biosciences, Inc. AURA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Elevance Health’s current-year earnings implies a 12.4% increase from the year-ago reported figure. ELV beat earnings estimates in each of the last four quarters, with an average surprise of 2.8%. The consensus mark for its current-year revenues is pegged at $171.8 billion, which indicates a 0.9% year-over-year increase. The Zacks Consensus Estimate for Aura Biosciences’ current-year earnings suggests a 6.7% year-over-year improvement. It has witnessed two upward estimate revisions over the past 60 days against no movement in the opposite direction. AURA beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 1.6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH):Free Stock Analysis Report Amedisys, Inc. (AMED):Free Stock Analysis Report Aura Biosciences, Inc. (AURA):Free Stock Analysis Report Elevance Health, Inc. (ELV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...